Abstract: The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where A, Z, Y, RA, Linker and v have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts thereof in methods of treatment of the human or animal body, for example in the prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

Abstract: A compound of formula or a pharmaceutically acceptable salt thereof, wherein R is —C(O)Ar1, —C(R4)(R5)Ar1 or Ar3; R3 represents a group X—R10 or Ar2; X represents a bond or a group NR11; and R10 represents C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, each of which may be optionally substituted by one or more substituents independently selected from carboxyl, hydroxyl, —C(O)—R12, C3-6 cycloalkyl, morpholinyl, —NR13R14, —SR15, —OR16, phenyl and halophenyl, or R10 represents a C3-6 cycloalkylcarbonyl, —C(O)CH2CN, halophenylcarbonyl or trifluoromethylcarbonyl group. The compounds or compositions thereof are useful in the treatment or prophylaxis of autoimmune, inflammatory, proliferative and hyperproliferative diseases.

Abstract: The invention provides thieno[2,3-d]pyrimidinediones of general formula 1